骨髓增殖性肿瘤血栓形成机制研究进展(5)
[24] Charpentier A，Lebreton A，Rauch A，et al. Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia [J]. Haematologica，2016，101(9)：e365-e368.
[25] Taniguchi Y，Tanaka H，Luis EJ，et al. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms [J]. Int J Hematol，2017，106(5)：691-703.
[26] Dahabreh IJ，Zoi K，Giannouli S，et al. Is JAK2 V617F mutation more than a diagnostic index？ A meta-analysis of clinical outcomes in essential thrombocythemia [J]. Leuk Res，2009，33(1)：67-73.
[27] Bertozzi I，Bogoni G，Biagetti G，et al. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden [J]. Ann Hematol，2017，96(8)：1297-1302.
[28] Dentali F，Squizzato A，Brivio L，et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism：a meta-analysis [J]. Blood，2009，113(22)：5617-5623.
[29] Palandri F，Latagliata R，Polverelli N，et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis [J]. Leukemia，2015，29(6)：1344-1349.
[30] Torregrosa JM，Ferrer-Marin F，Lozano ML，et al. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation [J]. Br J Haematol，2016，172(5)：813-815.
[31] Vannucchi AM，Antonioli E，Guglielmelli P，et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia [J]. Blood，2008，112(3)：844-847.
(收稿日期：2018-12-17 本文編辑：张瑜杰), 百拇医药(刘严慈 孙鹏慧 卢朝阳 惠吴函)
[25] Taniguchi Y，Tanaka H，Luis EJ，et al. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms [J]. Int J Hematol，2017，106(5)：691-703.
[26] Dahabreh IJ，Zoi K，Giannouli S，et al. Is JAK2 V617F mutation more than a diagnostic index？ A meta-analysis of clinical outcomes in essential thrombocythemia [J]. Leuk Res，2009，33(1)：67-73.
[27] Bertozzi I，Bogoni G，Biagetti G，et al. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden [J]. Ann Hematol，2017，96(8)：1297-1302.
[28] Dentali F，Squizzato A，Brivio L，et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism：a meta-analysis [J]. Blood，2009，113(22)：5617-5623.
[29] Palandri F，Latagliata R，Polverelli N，et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis [J]. Leukemia，2015，29(6)：1344-1349.
[30] Torregrosa JM，Ferrer-Marin F，Lozano ML，et al. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation [J]. Br J Haematol，2016，172(5)：813-815.
[31] Vannucchi AM，Antonioli E，Guglielmelli P，et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia [J]. Blood，2008，112(3)：844-847.
(收稿日期：2018-12-17 本文編辑：张瑜杰), 百拇医药(刘严慈 孙鹏慧 卢朝阳 惠吴函)